Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases.
about
Tissue engineering tools for modulation of the immune responseDesigner gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferEmerging PEGylated drugs.PEGylation of interleukin-10 for the mitigation of enhanced pain states.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblastsSmall sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapyEngineering biomaterial systems to enhance viral vector gene delivery.Effects of aging, TNF-α, and exercise training on angiotensin II-induced vasoconstriction of rat skeletal muscle arterioles.TNFalpha blockade in human diseases: mechanisms and future directions.Cytokines and the early vein graft: strategies to enhance durability.FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic ratsPEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.Product development issues for PEGylated proteins.Antagonists of TNF action: clinical experience and new developments.PEGylated drugs in rheumatology--why develop them and do they work?Preparation and investigation of high solid content PTX-loaded nanoparticles dispersion via nanoprecipitation method.Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.TNF-alpha and shear stress-induced large artery adaptations.Intermolecular interactions during ultrafiltration of pegylated proteins.Production of PEGylated Proteins
P2860
Q27023419-07F76C44-EF36-474E-BC89-3908724A6429Q33296224-826341D8-92A9-47F7-AD28-2772D98665F4Q33447691-A3BC6379-9144-49DF-A82A-8CAA586A5D18Q33505369-93FA3C45-308C-4974-A27A-4AA640ED48F2Q34069571-6BCECAE1-8965-4107-BD6F-05B9F66652E4Q34896053-21390EE6-DFF5-4440-845D-DA8FB1E8861EQ35086515-3501DA28-8739-4016-B283-45523BCA5783Q35144415-ACD04DF8-2F77-4018-B083-3796D849B676Q36366824-AC8230E1-E4F2-462B-80D3-69A956A79E98Q36536886-6A0DA782-E8C5-4306-AAD6-1CDBD8398E1BQ36837890-E1779C0C-8CE7-42E3-96C8-2099C6A053BBQ37141739-11AAE7AC-3E70-4689-B892-E908FBFBDE33Q37708777-0933CB54-4D10-419D-ADEF-EBAD941685ABQ37790702-19B95861-578D-46A6-B0BF-56796E2B526AQ38089191-0A8B1A78-D774-4E2B-A285-0C6BC4A27FB8Q38130374-69C6C870-7298-43EA-93CE-54313B1899AEQ38988509-2AD53557-D32C-416B-8C74-944D13890A2EQ39906629-43E3A1CA-7A0D-4FCE-B880-2C9EB517D19BQ42014279-514CF710-E36F-461A-9356-67169DF8BCEAQ42588233-68EE90CE-AB38-4603-BF37-FA60F5206702Q45892259-BDB91A7A-792E-459E-9AED-05B6CEF2C933Q57635944-660789FF-4C44-4A24-9F22-2C7C1DF053DC
P2860
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@ast
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@en
type
label
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@ast
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@en
prefLabel
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@ast
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@en
P2093
P1476
Design of PEGylated soluble tu ...... chronic inflammatory diseases.
@en
P2093
Alison M Bendele
Carl K Edwards
James Seely
Mary Ellen Cosenza
Olaf Kinstler
Scott Buckel
Steven W Martin
Tadahiko Kohno
Ulrich Feige
P304
P356
10.1016/S0169-409X(03)00112-1
P407
P577
2003-09-01T00:00:00Z